Sinopharm Group Co Ltd Class H (HK:1099)
:1099
Want to see HK:1099 full AI Analyst Report?
Top Page
Sinopharm Group Co
(1099)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$16.50
▼(-18.64% Downside)
Action:Downgraded
Date:04/25/26
The score is held back mainly by weak recent financial momentum (margin compression, slight revenue contraction, rising leverage) and bearish technical signals (below major moving averages with negative MACD). These risks are partially offset by an attractive valuation (low P/E) and a supportive dividend yield.
Positive Factors
Nationwide distribution network
A broad nationwide distribution network and long-standing relationships with hospitals, pharmacies and manufacturers create durable scale benefits. This supports recurring revenue, procurement advantages and higher barriers to entry, sustaining stable core volumes and service revenues over months.
Negative Factors
Revenue contraction
Recent flat-to-declining top line weakens scale economics vital for distribution margins. Reduced revenue growth limits pricing leverage and volume-driven procurement benefits, constraining margin recovery and investment capacity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Nationwide distribution network
A broad nationwide distribution network and long-standing relationships with hospitals, pharmacies and manufacturers create durable scale benefits. This supports recurring revenue, procurement advantages and higher barriers to entry, sustaining stable core volumes and service revenues over months.
Read all positive factors
Sinopharm Group Co (1099) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$49.28B
Dividend Yield3.75%
Average Volume (3M)4.67M
Price to Earnings (P/E)6.0
Beta (1Y)0.76
Revenue Growth-1.57%
EPS Growth1.55%
CountryHK
Employees108,217
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)2.29
Shares Outstanding1,341,810,800
10 Day Avg. Volume3,523,930
30 Day Avg. Volume4,674,378
Financial Highlights & Ratios
PEG Ratio5.74
Price to Book (P/B)0.65
Price to Sales (P/S)0.09
P/FCF Ratio4.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.28Price Target Upside14.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.43
Revenue Forecast (FY)HK$592.91B
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are ...
How the Company Makes Money
Sinopharm makes money mainly by acting as a large-scale distributor and supply-chain service provider for healthcare products in China. Its core revenue comes from (1) pharmaceutical distribution: purchasing medicines from drug manufacturers and s...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
60
Neutral
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 575.17B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 41.67B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 19.26B | 20.17B | 26.90B | 26.25B | 24.68B |
| Net Income | 7.16B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | |||||
| Total Assets | 390.53B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 61.59B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 108.63B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 256.31B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 83.99B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | |||||
| Free Cash Flow | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Negative
20.28
Price Trends
17.06
Negative
18.49
Negative
18.58
Negative
Market Momentum
-0.36
Negative
37.70
Neutral
29.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1099, the sentiment is Negative. The current price of 20.28 is above the 20-day moving average (MA) of 16.03, above the 50-day MA of 17.06, and above the 200-day MA of 18.58, indicating a bearish trend. The MACD of -0.36 indicates Negative momentum. The RSI at 37.70 is Neutral, neither overbought nor oversold. The STOCH value of 29.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1099.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$4.80B | 12.49 | 6.89% | 2.72% | 15.04% | 5.57% | |
60 Neutral | HK$59.87B | 9.74 | 7.64% | 2.67% | 6.45% | 35.60% | |
57 Neutral | HK$49.28B | 5.98 | 8.70% | 3.75% | -1.57% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$729.00M | 13.94 | 7.66% | 8.03% | -1.11% | -13.09% | |
41 Neutral | HK$582.60M | -4.03 | 480.37% | ― | -17.39% | -45.76% | |
40 Underperform | HK$989.11M | 24.60 | 1.09% | 3.81% | -10.71% | -87.93% |
* Healthcare Sector Average
HK:1099
Sinopharm Group Co
15.79
-1.70
-9.71%
HK:0673
China Health Group
0.42
0.18
75.00%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.63
0.36
3.20%
HK:1931
IVD Medical Holding Limited
0.61
-1.59
-72.27%
HK:2192
Medlive Technology Co., Ltd.
6.48
-7.77
-54.52%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
6.75
0.12
1.76%
Sinopharm Group Co Corporate Events
Sinopharm Sets Final 2025 Dividend and Clarifies Withholding Tax for H-Share Investors
Jun 18, 2026
Sinopharm Group has proposed a final ordinary cash dividend of RMB 0.69 per share for the financial year ended 31 December 2025, equivalent to HKD 0.79 per share based on an exchange rate of RMB 1 to HKD 1.15, with shareholder approval obtained on...
Sinopharm Shareholders Approve 2025 Results and Final Dividend at AGM
Jun 18, 2026
Sinopharm Group Co. Ltd. reported that its 2025 annual general meeting, along with separate class meetings for H shareholders and domestic shareholders, was held in Shanghai on 18 June 2026, with all board-attended resolutions passed by poll. Shar...
Sinopharm Sets 2025 AGM to Approve Dividend, Guarantees and Share Issuance Mandate
May 27, 2026
Sinopharm Group has called its 2025 annual general meeting for 18 June 2026 in Shanghai, where shareholders will review the board and supervisory committee reports, audited financial statements, and the proposed profit distribution and final divid...
Sinopharm Seeks Mandate to Repurchase Up to 10% of H Shares
May 27, 2026
Sinopharm Group has called an H shareholders’ class meeting in Shanghai on 18 June 2026 to seek approval for a special resolution granting its board a general mandate to repurchase up to 10% of the company’s H shares in issue, excludin...
Sinopharm Seeks Shareholder Mandate for Up to 10% H-Share Buyback
May 27, 2026
Sinopharm Group has convened a domestic shareholders’ class meeting for 18 June 2026 in Shanghai to seek approval for a special resolution granting its board a general mandate to repurchase up to 10% of the company’s H shares in issue,...
Sinopharm Accord’s First-Quarter Profit Drops as Revenue Slips and Cash Flow Weakens
Apr 29, 2026
Sinopharm subsidiary China National Accord Medicines reported first-quarter 2026 revenue of RMB 17.82 billion, down 2.57% year on year, reflecting modest top-line pressure in its pharmaceutical distribution business. Net profit attributable to sha...
Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base
Apr 27, 2026
Sinopharm Group Co. Ltd. has released unaudited consolidated and standalone financial information for the three months ended 31 March 2026, prepared under PRC GAAP, as required by regulators in the mainland and Hong Kong. The disclosure covers bal...
Sinopharm Medical Device Unit Sees Profit Decline Amid Modest Revenue Growth
Apr 23, 2026
Sinopharm subsidiary China National Medical Device Co. Ltd. reported modest top-line growth for the three months ended 31 March 2026, with revenue rising 1.23% year on year to RMB 16.999 billion and total assets up 3.82%. However, operating profit...
Sinopharm subsidiary posts steady Q1 profit growth but cash flow weakens
Apr 22, 2026
Sinopharm Group has disclosed key unaudited first-quarter figures for its Shanghai-listed subsidiary China National Medicines Corporation, showing steady year-on-year revenue growth and modest improvement in profitability. Revenue for the three mo...
Sinopharm Accord Q1 2026 Preliminary Results Show Profit Decline Amid Stable Asset Base
Apr 21, 2026
Sinopharm Group has released preliminary unaudited first-quarter 2026 figures for its Shenzhen-listed subsidiary Sinopharm Accord, showing a slight contraction in top-line performance alongside softer profitability metrics. The update offers inves...
Sinopharm Sets April Board Meeting to Approve First-Quarter 2026 Results
Apr 10, 2026
Sinopharm Group has scheduled a board meeting for April 24, 2026, to review and approve the unaudited quarterly results for the three months ended March 31, 2026. The announcement signals the forthcoming release of key financial data that will off...
Sinopharm Subsidiary Sinopharm Accord Posts Sharp 2025 Profit Rebound Despite Weaker Cash Flow
Apr 1, 2026
Sinopharm Group has disclosed the 2025 audited financial results of its Shenzhen-listed subsidiary, Sinopharm Accord, highlighting its position in the Chinese pharmaceutical distribution and healthcare sector. The company reported modest asset and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.